enGene Holdings Inc. (NASDAQ:ENGN) Stock Has Average Target Price of $11.05

Shares of enGene Holdings Inc. (NASDAQ:ENGN) have been given an average rating of “Hold” by the fourteen brokerages that are presently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $11.05.

ENGN has been the topic of a number of research analyst reports. Citigroup downgraded enGene from a “market perform” rating to a “hold” rating in a report on Friday. Citizens Jmp reissued a “market perform” rating on shares of enGene in a research report on Wednesday, September 9th. HC Wainwright reiterated a “buy” rating on shares of enGene in a research note on Friday. Jefferies Financial Group upgraded shares of enGene to a “strong-buy” rating in a research report on Tuesday, October 13th. Finally, Wall Street Zen upgraded shares of enGene from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 15th.

Institutional Trading of enGene

Hedge funds have recently bought and sold shares of the company. Perceptive Advisors LLC increased its position in shares of enGene by 179.8% during the 4th quarter. Perceptive Advisors LLC now owns 5,869,076 shares of the company’s stock valued at $52,998,000 after purchasing an additional 3,771,840 shares during the last quarter. Siren L.L.C. boosted its holdings in shares of enGene by 57.5% in the first quarter. Siren L.L.C. now owns 5,253,159 shares of the company’s stock worth $35,774,000 after buying an additional 1,916,895 shares during the last quarter. Cormorant Asset Management LP grew its position in enGene by 72.1% during the fourth quarter. Cormorant Asset Management LP now owns 4,000,000 shares of the company’s stock valued at $36,120,000 after buying an additional 1,676,405 shares during the period. Eventide Asset Management LLC bought a new stake in enGene during the fourth quarter valued at approximately $8,578,000. Finally, SR One Capital Management LP purchased a new stake in enGene during the second quarter valued at approximately $1,293,607. Hedge funds and other institutional investors own 64.16% of the company’s stock.

More enGene News

Here are the key news stories impacting enGene this week:

• Positive Sentiment: Jefferies upgrade: Jefferies Financial Group upgraded enGene, potentially improving investor sentiment and signaling a more favorable view of the company’s prospects or valuation. The article does not specify the new rating or price target. enGene Upgraded at Jefferies Financial Group
• Positive Sentiment: Preclinical and clinical-case-study discussion: enGene presented data and case studies involving a surfactant bladder rinse intended to improve delivery of its treatment. Additional evidence supporting the company’s investigational platform could help its outlook, although the information remains early-stage and does not establish definitive clinical efficacy. enGene Discusses Preclinical Data and Clinical Case Studies
• Neutral Sentiment: Company materials: A Yahoo Finance page lists enGene press releases, but the supplied entry does not identify a specific new announcement likely to materially affect the shares. enGene press releases
• Negative Sentiment: Existing financial pressure remains: enGene’s latest reported quarterly loss missed analyst expectations, and analysts expect another substantial loss for the full year. This limits the impact of the upgrade and keeps execution, cash usage and clinical progress important risks for investors.

enGene Price Performance

Shares of enGene stock opened at $1.67 on Monday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 10.21 and a current ratio of 10.21. The stock has a market capitalization of $111.92 million, a PE ratio of -0.81 and a beta of -0.29. enGene has a 52-week low of $1.40 and a 52-week high of $12.25. The company has a 50-day simple moving average of $1.83 and a two-hundred day simple moving average of $2.80.

enGene (NASDAQ:ENGN) last posted its quarterly earnings results on Tuesday, September 8th. The company reported ($0.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.04). On average, analysts anticipate that enGene will post -1.81 EPS for the current fiscal year.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.